A laboratory study in fission yeast linked caffeine exposure to indirect activation of components of the AMP-activated protein kinase (AMPK) pathway, faster mitotic division and increased chronological lifespan in the yeast model. The research was published in Microbial Cell on 24 June 2025 and also found that caffeine’s effects on DNA-damage sensitivity could be separated from its effects on mitosis in AMPK-pathway mutants.
The result concerns a single-celled fungal model, not people. It does not show that drinking caffeine extends human lifespan or healthspan, and the supplied study information does not establish the precise molecular target through which caffeine activates the pathway.
Contents
What the study found
The study examined caffeine’s effects on cell-cycle regulation, DNA-damage sensitivity and chronological lifespan in fission yeast. Fission yeast is a single-celled fungal model used to investigate conserved processes such as cell-cycle control and responses to cellular stress.
The authors report that caffeine indirectly activated three components of the AMPK pathway: Ssp1, Ssp2 and the AMPK beta regulatory subunit Amk2. Following caffeine exposure, Ssp2 became phosphorylated in an Ssp1-dependent manner.
The researchers also report that caffeine accelerated mitotic division through AMPK signalling. Mitosis is the stage of the cell cycle in which a cell separates its duplicated genetic material before dividing.
The study identified a separate effect under prolonged genotoxic stress—conditions in which cells experience sustained exposure to factors that damage DNA. Ssp1 and Amk2 were required for resistance to caffeine in those conditions. In AMPK-pathway mutants, caffeine’s effects on DNA-damage sensitivity became uncoupled from its effects on mitosis. In other words, the two responses did not necessarily represent one indivisible downstream process.
The authors further propose that caffeine may interact synergistically with other genotoxic agents to increase DNA-damage sensitivity. That is an attributed interpretation from the study; the supplied information does not provide the quantitative results or experimental conditions needed to assess the size of this proposed interaction.
Finally, the study reports that caffeine benefited chronological lifespan through AMPK in the fission-yeast model. A chronological-lifespan assay measures how long non-dividing cells remain viable under a defined laboratory condition. It is different from measuring the lifespan of an intact animal or human.
How the pathway fits
AMPK is a conserved cellular energy-sensing pathway. It can respond to nutritional and other forms of stress and influence metabolism and cell-cycle regulation. In the interpretation presented by the paper, caffeine indirectly activates an Ssp1–Ssp2–Amk2 AMPK pathway rather than simply acting through a direct inhibition mechanism.
The paper discusses earlier hypotheses that caffeine might inhibit Rad3, a DNA-damage checkpoint kinase in fission yeast, or modulate cell cycle and lifespan by inhibiting TORC1. TORC1 is a nutrient- and stress-responsive signalling complex that regulates aspects of cellular growth and metabolism.
The new interpretation instead places AMPK signalling near the centre of caffeine’s effects in this model. The article’s technical context links AMPK activity to mitotic timing through inhibition of Sck2, a downstream signalling component. However, the supplied study information does not establish whether caffeine directly affects TORC1, Rad3, another upstream regulator or the pathway through a different molecular interaction.
This distinction matters because observing an outcome after caffeine exposure does not by itself identify caffeine’s direct molecular target. The study’s evidence supports indirect activation of AMPK-pathway components, while the initiating step remains unresolved.
What the result does and does not show
The findings provide a possible connection between caffeine exposure, cellular stress signalling, cell-cycle timing and survival of non-dividing yeast cells. They may help clarify why caffeine can produce more than one cellular response: faster mitotic progression, altered sensitivity to prolonged DNA damage and a change in chronological lifespan.
They do not establish an anti-ageing effect in humans. The experiments used fission yeast and did not report human participants, clinical outcomes or improved healthspan in an animal or person. Although AMPK is conserved across many organisms, conservation of a pathway does not demonstrate that the same exposure produces the same physiological result in humans.
The result also should not be read as evidence that caffeine is beneficial under all conditions. In the study, caffeine was associated with altered DNA-damage sensitivity, and the authors proposed an interaction with other genotoxic agents. The supplied information does not provide the concentrations, exposure durations, number of biological replicates, dose-response relationship or quantitative lifespan effect sizes needed to evaluate the result fully.
A longer chronological lifespan in yeast is also not equivalent to a longer lifespan in an intact organism. Non-dividing-cell survival in a defined assay captures only one aspect of ageing biology and does not measure the coordinated functions of tissues, organs or immune and nervous systems.
The results therefore do not support using caffeine as an anti-ageing treatment or changing caffeine intake for lifespan purposes.